Elacestrant: who are optimal candidates for the first oral SERD?

Ann Oncol. 2023 May;34(5):449-451. doi: 10.1016/j.annonc.2023.02.006. Epub 2023 Feb 20.

Authors

M Lipsyc-Sharf¹, S M Tolaney²

Affiliations

¹ Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA.
² Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: Sara_Tolaney@dfci.harvard.edu.

PMID: 36813113
DOI: 10.1016/j.annonc.2023.02.006

No abstract available

Publication types

Editorial

MeSH terms

Breast Neoplasms*
Estrogen Receptor alpha
Female
Humans
Tetrahydronaphthalenes*

Substances

elacestrant
Tetrahydronaphthalenes
Estrogen Receptor alpha